Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: IGIT2/21 - Immunopathology of GIT

Deadline: 25.10.2021

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N_{rel}

Set 1

(420) Anti-gliadin IgG (native)

A1	(2) EIA methods	>>>	19	Negative	100 %
	Total per sample: n = 19 — Success: 100 %				
B1	(2) EIA methods	>>>	19	Positive	100 %
	Total per sample: n = 19 — Success: 100 %				

Total success: 100 %

(421) Anti-gliadin IgA (native)

A1	(2) EIA methods	>>>	16	Negative	89 %
			1	Inconclusive result (borderline)	5,6 %
			1	Positive	5,6 %
	Total per sample: n = 18 — Success: 89 %				
B1	(2) EIA methods	>>>	18	Positive	100 %
	Total per sample: n = 18 — Success: 100 %				

Total success: 89 %

(594) Anti-gliadin IgG (deamidated)

A1	(1) Fluorescent methods	>>>	1	Negative	1,3 %
			1	Inconclusive result (borderline)	1,3 %
	(2) EIA methods	>>>	61	Negative	81 %
			1	Positive	1,3 %
	(5) LIA, ILMA	>>>	9	Negative	12 %
	(99) Another measurement principle	>>>	2	Negative	2,7 %
	Total per sample: n = 75 — Success: 97 %				
B1	(1) Fluorescent methods	>>>	2	Positive	2,7 %
	(2) EIA methods		2	Negative	2,7 %
		>>>	60	Positive	80 %
	(5) LIA, ILMA	>>>	9	Positive	12 %
	(99) Another measurement principle	>>>	2	Positive	2,7 %
	Total per sample: n = 75 — Success: 97 %				

Total success: 95 %

(595) Anti-gliadin IgA (deamidated)

A1	(1) Fluorescent methods	>>>	2	Negative	2,8 %
	(2) EIA methods	>>>	58	Negative	82 %
			1	Positive	1,4 %
	(5) LIA, ILMA	>>>	8	Negative	11 %
	(99) Another measurement principle	>>>	2	Negative	2,8 %
	Total per sample: n = 71 — Success: 99 %				
B1	(1) Fluorescent methods	>>>	2	Positive	2,8 %
	(2) EIA methods		1	Negative	1,4 %
			1	Inconclusive result (borderline)	1,4 %
		>>>	57	Positive	80 %
	(5) LIA, ILMA	>>>	8	Positive	11 %
	(99) Another measurement principle	>>>	2	Positive	2,8 %
	Total per sample: n = 71 — Success: 97 %				

Total success: 96 %

Set 2

(424) Anti-endomysium IgA

A2	(1) Fluorescent methods	>>>	67	Negative	99 %
	(2) EIA methods	>>>	1	Negative	1,5 %
	Total per sample: n = 68 — Success: 100 %				
B2	(1) Fluorescent methods	>>>	67	Positive	99 %
	(2) EIA methods	>>>	1	Positive	1,5 %
	Total per sample: n = 68 — Success: 100 %				

Total success: 100 %

(425) Anti-transglutaminase IgA

A2	(1) Fluorescent methods	>>>	1	Negative	1,2 %
	(2) EIA methods	>>>	63	Negative	77 %
			1	Inconclusive result (borderline)	1,2 %
	(5) LIA, ILMA	>>>	16	Negative	20 %
	(99) Another measurement principle	>>>	1	Negative	1,2 %
	Total per sample: n = 82 — Success: 99 %				
B2	(1) Fluorescent methods	>>>	1	Positive	1,2 %
	(2) EIA methods	>>>	64	Positive	78 %

Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: IGIT2/21 - Immunopathology of GIT

Test

Sample	Group		N	Result	N_{rel}
B2	(5) LIA, ILMA	>>>	16	Positive	20 %
	(99) Another measurement principle	>>>	1	Positive	1,2 %
	Total per sample: n = 82 — Success: 100 %				

Total success: 99 %

Set 3

(592) Anti-Saccharomyces cerevisiae IgA

Sample	Group		N	Result	N_{rel}
A3	(1) Fluorescent methods	>>>	20	Positive	33 %
	(2) EIA methods	>>>	39	Positive	65 %
	(5) LIA, ILMA	>>>	1	Positive	1,7 %
	Total per sample: n = 60 — Success: 100 %				
B3	(1) Fluorescent methods	>>>	20	Negative	33 %
	(2) EIA methods	>>>	39	Negative	65 %
	(5) LIA, ILMA	>>>	1	Negative	1,7 %
	Total per sample: n = 60 — Success: 100 %				

Total success: 100 %

(593) Anti-Saccharomyces cerevisiae IgG

Sample	Group		N	Result	N_{rel}
A3	(1) Fluorescent methods		1	Negative	1,8 %
		>>>	17	Positive	31 %
	(2) EIA methods	>>>	36	Positive	65 %
	(5) LIA, ILMA	>>>	1	Positive	1,8 %
	Total per sample: n = 55 — Success: 98 %				
B3	(1) Fluorescent methods	>>>	18	Negative	33 %
	(2) EIA methods	>>>	36	Negative	65 %
	(5) LIA, ILMA	>>>	1	Negative	1,8 %
	Total per sample: n = 55 — Success: 100 %				

Total success: 98 %